BR-1733

N/A

Report date: 2024/09/12 16:15:43
NME

Base Information

Drug NameBR-1733
Drug Alias NameBR1733BR-1733
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPolycomb protein EED inhibitors
TargetsPolycomb protein EED
Therapy Area/IndicationsLymphoma, T-Cell, PeripheralLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Blueray Biopharma Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Blueray Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, T-Cell, PeripheralLymphoma, FollicularLymphoma, Large B-Cell, Diffuse
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A